Pyoderma gangrenosum - I-Pyoderma Gangrenosum
I- I-Pyoderma Gangrenosum (Pyoderma gangrenosum) isifo sesikhumba esingavamile, esivuvukalayo lapho ama-pustules abuhlungu noma amaqhuqhuva eba izilonda ezikhula kancane kancane. I- i-pyoderma gangrenosum (pyoderma gangrenosum) ayitheleleki. Ukwelashwa kungase kuhlanganise i-corticosteroids, i-ciclosporin, noma amasosha omzimba ahlukahlukene e-monoclonal. Nakuba kungathinta abantu banoma iyiphi iminyaka, kuthinta kakhulu abantu abaneminyaka engu-40 no-50.
☆ Emiphumeleni ka-2022 ye-Stiftung Warentest evela eJalimane, ukwaneliseka kwabathengi nge-ModelDerm bekungaphansi kancane kunokuxhumana okukhokhelwayo kwe-telemedicine.
Emlenzeni womuntu one-ulcerative colitis.
References
I- Pyoderma gangrenosum yisimo sesikhumba esingandile esidala izilonda ezibuhlungu ezinemiphetho ebomvu noma ensomi. Kubhekwa njengesifo sokuvuvukala futhi kuyingxenye yeqembu elibizwa ngokuthi ama-neutrophilic dermatoses. Imbangela ye- pyoderma gangrenosum iyinkimbinkimbi, ehlanganisa izinkinga zakho kokubili ukungatheleleki okungokwemvelo nokuguquguqukayo kubantu abathambekele kufuzo. Muva nje, abacwaningi bagxile ku-follicule yezinwele njengesiqalo esingaba khona salesi sifo.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum yisimo sesikhumba esingandile esidala izilonda ezibuhlungu kakhulu. Nakuba singaqondi ngokugcwele imbangela yayo, siyazi ukuthi ihilela ukwanda komsebenzi wamaseli athile omzimba. Ukwelapha lesi sifo akukabi lula. Sinemithi ehlukahlukene ecindezela amasosha omzimba noma eshintsha ukusebenza kwawo. Ngokuhambisana nalokhu, siphinde sigxile ekwelapheni amanxeba nokulawula izinhlungu. I-Corticosteroids ne-cyclosporine kuvame ukuba yinketho yokuqala yokwelashwa, kodwa kamuva nje, kube nocwaningo olwengeziwe mayelana nokusebenzisa izindlela zokwelapha ze-biologic njenge-TNF-α inhibitors. Lawa ma-biologics aya ngokuthandwa kakhulu, ikakhulukazi ezigulini ezinezinye izimo ezivuvukalayo, futhi asetshenziswa ekuqaleni kwenqubo yesifo.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
